An EUA for Bebtelovimab for Treatment of COVID-19

Date: March 21, 2022
Issue #: 
1646Summary: 
The investigational monoclonal antibody
bebtelovimab (LY-CoV1404 – Lilly) has been granted
an FDA Emergency Use Authorization (EUA) for IV
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at high
risk of progressing to severe disease, including
hospitalization and death, and for whom alternative
treatment options are unavailable or inappropriate.
Bebtelovimab is active against the Omicron variant of
SARS-CoV-2; sotrovimab (VIR-7831) is the only other
monoclonal antibody currently available for treatment
of COVID-19 that is active against Omicron.

Source: The Medical Letter - February 17, 2022 Category: Drugs & Pharmacology Authors: admin Tags: bamlanivimab bebtelovimab COVID-19 etesevimab molnupiravir nirmatrelvir Paxlovid remdesivir Ritonavir sotrovimab Veklury Source Type: research